知镜 Cognispect · 医学文献与研究工作台

Biomarker changes in cerebral adrenoleukodystrophy after gene therapy or allogeneic hematopoietic cell transplant.

Lund TC, Kemp S, Alikhani P, Willmert A, Braun J, Gupta A, Loes DJ, Nascene DR, Orchard PJ.
Molecular therapy. Advances · 2026-07-29 · PMID 42662429

文献摘要

Cerebral adrenoleukodystrophy (CALD) is a progressive immune-inflammatory neurologic disease that can be arrested with autologous hematopoietic cell transplant-based gene therapy (GT) or allogeneic hematopoietic cell transplantation (Allo-HCT). We compared transplant types by evaluating changes in two biomarkers, C26:0-lysophosphatidylcholine (C26:0-lysoPC) and neurofilament light chain (NfL), before and 12 months after therapy. Disease severity was quantified by Loes score on MRI. Baseline C26:0-lysoPC was 489 nmol/L for GT recipients and 487 nmol/L for Allo-HCT recipients; it decreased by 6.7% after GT and 48.4% after Allo-HCT ( p p = 0.0006). Loes score progression was greater with GT (+3.0 vs. +1.0 points, p = 0.0134). Multivariate analyses to understand which pre-HCT variable was best associated with disease progression indicated that modality of transplant, GT, was the only significant factor ( p = 0.0302).

在知镜精读原文来源DOI 原文

知镜提供医学文献检索、阅读笔记、人体图谱、统计绘图与研究复现工具。